Literature DB >> 10490761

Expression of coxsackie adenovirus receptor and alphav-integrin does not correlate with adenovector targeting in vivo indicating anatomical vector barriers.

H Fechner1, A Haack, H Wang, X Wang, K Eizema, M Pauschinger, R Schoemaker, R Veghel, A Houtsmuller, H P Schultheiss, J Lamers, W Poller.   

Abstract

Recombinant adenoviral vectors are broadly applied in gene therapy protocols. However, adenovector-mediated gene transfer has limitations in vivo. One of these is the low gene transfer rate into organs other than the liver after systemic intravenous vector injection. Local direct injection into the target organ has been used as one possible solution, but increases necessary equipment and methodology and is traumatic to the target. Wild-type adenovirus infection as well as adenovector-mediated gene transfer depends on virus interaction with the Coxsackie adenovirus receptor (CAR) mediating virus attachment to the cell surface, and on interaction with alphavbeta3 and alphavbeta5 integrins mediating virus entry into the cell. In order to assess the receptor-associated potential of different tissues to act as adenovector targets, we have therefore determined CAR and alphav-integrin expression in multiple organs from different species. In addition, we have newly determined several human, rat, pig and dog CAR-mRNA sequences. Sequence comparison and structural analyses of known and of newly determined sequences suggests a potential adenovirus binding site between amino acids 29 and 128 of the CAR. With respect to the virus receptor expression patterns we found that CAR-mRNA expression was extremely variable between different tissues, with the highest levels in the liver, whereas alphav-integrin expression was far more homogenous among different organs. Both CAR and alphav-integrin showed similar expression patterns among different species. There was no correlation, however, between the adenovector expression patterns after intravenous, intracardiac and aortic root injection, respectively, and the virus receptor patterns. In summary, many organs carry both receptors required to make them potential adenovector targets. In sharp contrast, their actual targeting clearly indicates that adenovirus receptor expression is necessary but not sufficient for vector transfer after systemic injection. The apparently very important role of anatomical barriers, in particular the endothelium, requires close attention when developing non-traumatic, organ-specific gene therapy protocols.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10490761     DOI: 10.1038/sj.gt.3301030

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  65 in total

1.  Dependence of adenovirus infectivity on length of the fiber shaft domain.

Authors:  D M Shayakhmetov; A Lieber
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

2.  Artificial extension of the adenovirus fiber shaft inhibits infectivity in coxsackievirus and adenovirus receptor-positive cell lines.

Authors:  Toshiro Seki; Igor Dmitriev; Elena Kashentseva; Koichi Takayama; Marianne Rots; Kaori Suzuki; David T Curiel
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

3.  Reducing the native tropism of adenovirus vectors requires removal of both CAR and integrin interactions.

Authors:  D A Einfeld; R Schroeder; P W Roelvink; A Lizonova; C R King; I Kovesdi; T J Wickham
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

4.  The coxsackievirus and adenovirus receptor is a transmembrane component of the tight junction.

Authors:  C J Cohen; J T Shieh; R J Pickles; T Okegawa; J T Hsieh; J M Bergelson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-04       Impact factor: 11.205

Review 5.  Cell physiology as a variable in gene transfer to endothelium.

Authors:  Philip L Leopold
Journal:  Curr Atheroscler Rep       Date:  2003-05       Impact factor: 5.113

6.  Reduction of natural adenovirus tropism to mouse liver by fiber-shaft exchange in combination with both CAR- and alphav integrin-binding ablation.

Authors:  Naoya Koizumi; Hiroyuki Mizuguchi; Fuminori Sakurai; Teruhide Yamaguchi; Yoshiteru Watanabe; Takao Hayakawa
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

7.  Optimization of adenoviral vectors to direct highly amplified prostate-specific expression for imaging and gene therapy.

Authors:  Makoto Sato; Mai Johnson; Liqun Zhang; Baohui Zhang; Kim Le; Sanjiv S Gambhir; Michael Carey; Lily Wu
Journal:  Mol Ther       Date:  2003-11       Impact factor: 11.454

8.  Magnetic nanoparticles enhance adenovirus transduction in vitro and in vivo.

Authors:  Cédric Sapet; Christophe Pellegrino; Nicolas Laurent; Flavie Sicard; Olivier Zelphati
Journal:  Pharm Res       Date:  2011-12-07       Impact factor: 4.200

9.  Gene therapy to the kidney using viral vectors.

Authors:  Talha Akbulut; Frank Park
Journal:  Paidiatrike       Date:  2008

10.  A zebrafish coxsackievirus and adenovirus receptor homologue interacts with coxsackie B virus and adenovirus.

Authors:  JenniElizabeth Petrella; Christopher J Cohen; Jedidiah Gaetz; Jeffrey M Bergelson
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.